Regeneron, Sanofi drug slashes cholesterol in late-stage trial

By Ransdell Pierson (Reuters) – A new type of cholesterol drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of “bad” LDL cholesterol almost in half in the first of a dozen late-stage trials of the injectable medicine. The experimental drug, called alirocumab, is from a promising new class of injectable cholesterol fighters also being developed by Amgen Inc and other drugmakers. …